Ronald Blue Co Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Ronald Blue Co reduced its stake in Eli Lilly and Co by 8.83% during the most recent quarter end. The investment management company now holds a total of 52,677 shares of Eli Lilly and Co which is valued at $4,225,749 after selling 5,100 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.Eli Lilly and Co makes up approximately 0.19% of Ronald Blue Co’s portfolio.

Other Hedge Funds, Including , Edmond De Rothschild (suisse) S.a. boosted its stake in LLY in the latest quarter, The investment management firm added 810 additional shares and now holds a total of 5,530 shares of Eli Lilly and Co which is valued at $443,617. Eli Lilly and Co makes up approx 0.14% of Edmond De Rothschild (suisse) S.a.’s portfolio.Mcmillion Capital Management Inc reduced its stake in LLY by selling 8,185 shares or 18.06% in the most recent quarter. The Hedge Fund company now holds 37,126 shares of LLY which is valued at $3,029,482. Eli Lilly and Co makes up approx 2.25% of Mcmillion Capital Management Inc’s portfolio.Gabelli Funds reduced its stake in LLY by selling 32,000 shares or 5.5% in the most recent quarter. The Hedge Fund company now holds 550,000 shares of LLY which is valued at $44,858,000. Eli Lilly and Co makes up approx 0.27% of Gabelli Funds’s portfolio.Murphy Capital Management Inc reduced its stake in LLY by selling 1,100 shares or 7.02% in the most recent quarter. The Hedge Fund company now holds 14,559 shares of LLY which is valued at $1,168,797. Eli Lilly and Co makes up approx 0.18% of Murphy Capital Management Inc’s portfolio.Davenport Co boosted its stake in LLY in the latest quarter, The investment management firm added 4,002 additional shares and now holds a total of 32,528 shares of Eli Lilly and Co which is valued at $2,581,422. Eli Lilly and Co makes up approx 0.04% of Davenport Co’s portfolio.

Eli Lilly and Co closed down -0.72 points or -0.90% at $79.06 with 37,46,012 shares getting traded on Friday. Post opening the session at $79.55, the shares hit an intraday low of $78.78 and an intraday high of $79.79 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.